FLOT and CROSS chemotherapy regimens alter the frequency of CD27
CD27
CD69
DAMPs
Immune checkpoint inhibitors
Tumour microenvironment
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
14
06
2022
accepted:
11
08
2022
medline:
5
7
2023
pubmed:
21
8
2022
entrez:
20
8
2022
Statut:
ppublish
Résumé
Combining immunostimulatory chemotherapies with immunotherapy is an attractive strategy to enhance treatment responses in oesophagogastric junctional adenocarcinoma (OGJ). This study investigates the immunostimulatory properties of FLOT, CROSS and MAGIC chemotherapy regimens in the context of OGJ using in vitro and ex vivo models of the treatment-naïve and post-chemotherapy treated tumour microenvironment. FLOT and CROSS chemotherapy regimens increased surrogate markers of immunogenic cell death (HMGB1 and HLA-DR), whereas the MAGIC treatment regimen decreased HMGB1 and HLA-DR on OGJ cells (markedly for epirubicin). Tumour-infiltrating and circulating T cells had significantly lower CD27 expression and significantly higher CD69 expression post-FLOT and post-CROSS treatment. Similarly, the supernatant from FLOT- and CROSS-treated OGJ cell lines and from FLOT- and CROSS-treated OGJ biopsies cultured ex vivo also decreased CD27 and increased CD69 expression on T cells. Following 48 h treatment with post-FLOT and post-CROSS tumour conditioned media the frequency of CD69
Identifiants
pubmed: 35986757
doi: 10.1007/s00432-022-04283-9
pii: 10.1007/s00432-022-04283-9
pmc: PMC10314858
doi:
Substances chimiques
HMGB1 Protein
0
Culture Media, Conditioned
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3753-3774Subventions
Organisme : Irish Research Council for Science, Engineering and Technology
ID : GOIPG/2017/1659
Informations de copyright
© 2022. The Author(s).
Références
Immunity. 2008 Dec 19;29(6):934-46
pubmed: 19062317
Biol Pharm Bull. 2020;43(3):399-403
pubmed: 32115500
BMC Cancer. 2019 Nov 6;19(1):1053
pubmed: 31694582
Transl Oncol. 2021 Jun;14(6):101062
pubmed: 33765543
Future Oncol. 2019 Aug;15(23):2723-2731
pubmed: 31234645
Oncogene. 2016 Oct 13;35(41):5337-5349
pubmed: 26923327
Leuk Lymphoma. 2009 May;50(5):788-801
pubmed: 19452318
Gut. 2021 Feb;70(2):234-242
pubmed: 32554620
Ann N Y Acad Sci. 2010 Oct;1209:77-82
pubmed: 20958319
J Immunol Res. 2016;2016:8941260
pubmed: 27314056
Mol Cancer. 2014 Jul 05;13:165
pubmed: 24996221
J Thorac Dis. 2014 May;6 Suppl 2:S253-64
pubmed: 24868443
Genes Dis. 2018 May 17;5(3):194-203
pubmed: 30320184
Cancer Res. 2018 Aug 15;78(16):4573-4585
pubmed: 29752262
Int Immunol. 2018 Nov 14;30(12):559-567
pubmed: 30085193
J Clin Invest. 2010 Jan;120(1):168-78
pubmed: 19955658
Immunol Rev. 2009 May;229(1):216-31
pubmed: 19426224
Nat Rev Dis Primers. 2017 Jul 27;3:17048
pubmed: 28748917
J Exp Med. 2004 Jun 7;199(11):1595-605
pubmed: 15184507
Cancer Microenviron. 2019 Apr;12(1):57-66
pubmed: 30834503
Immunology. 1999 May;97(1):159-65
pubmed: 10447727
Blood. 2007 Jun 1;109(11):4810-5
pubmed: 17311995
Int Rev Cell Mol Biol. 2017;330:295-342
pubmed: 28215534
Cancer Cell. 2013 Mar 18;23(3):277-86
pubmed: 23518347
Ann Oncol. 2008 Nov;19(11):1882-7
pubmed: 18669868
Cancer Lett. 2020 Dec 28;495:89-99
pubmed: 32950619
Cancer Res. 2002 May 1;62(9):2592-9
pubmed: 11980654
J Immunother. 2010 Oct;33(8):769-79
pubmed: 20842060
J Exp Med. 2006 Sep 4;203(9):2145-55
pubmed: 16923852
Cancer Immunol Immunother. 2003 Oct;52(10):617-24
pubmed: 12802519
Int J Cancer. 2015 Mar 15;136(6):1381-9
pubmed: 25098891
World J Gastroenterol. 2022 Jun 7;28(21):2302-2319
pubmed: 35800186
Arthritis Res Ther. 2003;5(2):R91-6
pubmed: 12718752
Lancet. 2013 Feb 2;381(9864):400-12
pubmed: 23374478
Curr Opin Immunol. 2005 Jun;17(3):275-81
pubmed: 15886117
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Immunity. 2016 Feb 16;44(2):343-54
pubmed: 26872698
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Cancer Res. 2006 Feb 15;66(4):2328-37
pubmed: 16489038
Oncoimmunology. 2013 Sep 1;2(9):e25962
pubmed: 24327938
BMC Surg. 2008 Nov 26;8:21
pubmed: 19036143
Blood. 2007 Oct 1;110(7):2537-44
pubmed: 17615291
Clin Breast Cancer. 2000 Sep;1 Suppl 1:S46-51
pubmed: 11970749
Cancer Lett. 2018 Apr 10;419:210-221
pubmed: 29414305
Front Oncol. 2020 Jun 04;10:891
pubmed: 32582553
Cell Death Differ. 2014 Jan;21(1):15-25
pubmed: 23787994
J Recept Signal Transduct Res. 2019 Jun;39(3):208-214
pubmed: 31441696
Am J Pathol. 2004 Jan;164(1):315-23
pubmed: 14695344
Int J Mol Sci. 2021 Jan 22;22(3):
pubmed: 33499003
Cancer Res. 2012 Jul 15;72(14):3664-76
pubmed: 22628427
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686